GO:0016149 translation release factor activity, codon specific: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016149 describes a translation release factor activity that is specific for one or more particular termination codons and acts at the ribosomal A-site, requiring polypeptidyl-tRNA at the P-site.
• Codon-specific release factors recognize stop codons (UAA, UAG, UGA) and trigger hydrolysis of the peptidyl-tRNA bond to release the nascent polypeptide.
• In eukaryotes, eRF1 recognizes all three stop codons, while in bacteria RF1 and RF2 are codon-specific; mitochondrial release factors show distinct substrate specificity.
• Defects in translation termination are linked to nonsense mutation diseases, cancer, and mitochondrial disorders.
• Key experimental approaches include ribosome profiling, in vitro translation assays, and CRISPR knockout/knock-in models.
• EDITGENE provides CRISPR services to model codon-specific release factor activity, including knockout, point mutation, knock-in, and overexpression cell lines.
Description
Translation termination is a critical step in protein synthesis, ensuring that the ribosome releases the completed polypeptide at the correct stop codon. The Gene Ontology term GO:0016149, translation release factor activity, codon specific, defines a molecular function where a release factor specifically recognizes one or more termination codons and catalyzes peptide release at the ribosomal A-site, with a polypeptidyl-tRNA at the P-site. This activity is essential for accurate gene expression and proteome fidelity. In bacteria, release factors RF1 and RF2 are codon-specific, recognizing UAA/UAG and UAA/UGA, respectively, while in eukaryotes eRF1 recognizes all three stop codons. Mitochondrial release factors also exhibit distinct codon specificity. The study of codon-specific release factor activity has broad implications for understanding nonsense-mediated diseases, cancer, and mitochondrial disorders. Researchers leverage this term to annotate gene function, design experiments, and interpret ribosome profiling data. This article provides a comprehensive overview of GO:0016149, covering its definition, mechanism, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based models.
translation release factor activity, codon specific At A Glance
| GO ID | GO:0016149 |
|---|---|
| GO term | translation release factor activity, codon specific |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Codon-specific recognition of termination codons and catalysis of peptidyl-tRNA hydrolysis at the ribosomal A-site |
| Cellular location | Ribosome (A-site) |
| Substrates | Polypeptidyl-tRNA at P-site, stop codon at A-site |
| Products | Released polypeptide, tRNA, and ribosome |
| Cofactors | GTP (for some release factors), ribosomal proteins |
| Regulation | Modulated by eIF3, suppressor tRNAs, and ribosomal dynamics |
What Is GO:0016149?
GO:0016149, translation release factor activity, codon specific, is a molecular function ontology term describing a translation release factor that is specific for one or more particular termination codons. It acts at the ribosomal A-site and requires a polypeptidyl-tRNA at the P-site. This activity is responsible for recognizing stop codons and catalyzing the hydrolysis of the ester bond between the nascent polypeptide and the tRNA, leading to polypeptide release.
Why Is translation release factor activity, codon specific Important in Cell Biology?
Codon-specific release factor activity is fundamental to accurate translation termination, preventing readthrough of stop codons and ensuring proteome integrity. Dysregulation of this activity can lead to diseases such as nonsense mutation disorders, where premature stop codons cause truncated proteins. In cancer, mutations in release factors or their regulators can promote tumorigenesis through aberrant protein expression. Mitochondrial release factors are critical for mitochondrial function, and their defects are associated with mitochondrial diseases. Understanding GO:0016149 enables researchers to dissect translation termination mechanisms, develop therapeutic strategies for nonsense mutations, and interpret genomic data.
• Ensures accurate termination of protein synthesis at stop codons.
• Prevents readthrough of premature stop codons, which can cause disease.
• Plays a role in nonsense mutation diseases such as cystic fibrosis and Duchenne muscular dystrophy.
• Mitochondrial release factors are essential for mitochondrial gene expression and function.
• Codon-specific release factors are targets for antibiotic development in bacteria.
• Defects in termination can lead to ribosomopathies and cancer.
• Suppressor tRNAs can compete with release factors, modulating termination efficiency.
• Release factor activity is studied using ribosome profiling and in vitro assays.
• CRISPR models enable functional dissection of release factor genes.
• Understanding codon specificity aids in designing therapies for nonsense mutations.
Molecular Mechanism of translation release factor activity, codon specific
Stop Codon Recognition at the Ribosomal A-site
In simple terms: The release factor checks the codon in the ribosome's A-site to see if it is a stop signal.
Codon-specific release factors recognize termination codons (UAA, UAG, UGA) in the ribosomal A-site. In bacteria, RF1 recognizes UAA and UAG, while RF2 recognizes UAA and UGA; in eukaryotes, eRF1 recognizes all three stop codons. This recognition is mediated by specific amino acid residues that interact with the mRNA codon. The ribosome itself contributes to the fidelity of this process through conformational changes during decoding. Mitochondrial release factors exhibit distinct codon specificity, with some lacking response to UGA.
Peptidyl-tRNA Hydrolysis and Polypeptide Release
In simple terms: Once the stop codon is recognized, the release factor cuts the bond holding the new protein to the tRNA, freeing the protein.
After stop codon recognition, the release factor catalyzes the hydrolysis of the ester bond between the nascent polypeptide and the P-site tRNA. This reaction requires a polypeptidyl-tRNA at the P-site and is facilitated by the ribosome's peptidyl transferase center. The mechanism involves a conserved Gly-Gly-Gln (GGQ) motif in the release factor that positions a water molecule for nucleophilic attack. This step is essential for terminating translation and releasing the completed polypeptide.
Role of GTP and Ribosomal Factors
In simple terms: Some release factors need energy from GTP and help from other proteins to work properly.
In eukaryotes, eRF1 works in complex with eRF3, a GTPase, which stimulates peptide release. GTP hydrolysis by eRF3 is coupled to eRF1-mediated termination. In bacteria, RF1 and RF2 are assisted by RF3, another GTPase. The ribosome provides a platform for these interactions, and initiation factors like eIF3 can influence release factor loading. The accuracy of translocation and termination is also modulated by ribosomal dynamics.
Competition with Suppressor tRNAs and Readthrough
In simple terms: Sometimes a tRNA can read a stop codon and add an amino acid instead of stopping, which is called readthrough.
Suppressor tRNAs can compete with release factors for stop codon recognition, leading to stop codon readthrough and incorporation of an amino acid. This competition is influenced by the concentration of release factors and tRNAs, as well as the context of the stop codon. Site-specific release of nascent chains at a sense codon can also occur under certain conditions, highlighting the complexity of termination. Understanding this interplay is important for developing therapies that promote readthrough of premature stop codons.
Key Genes Involved in GO:0016149 translation release factor activity, codon specific
The following genes encode proteins with codon-specific translation release factor activity or directly regulate this process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RF1 (prfA) | Bacterial release factor recognizing UAA and UAG codons | Antibiotic target; model for codon specificity |
| RF2 (prfB) | Bacterial release factor recognizing UAA and UGA codons | Studied for termination mechanisms |
| RF3 (prfC) | GTPase that stimulates RF1/RF2 activity | Regulates termination efficiency |
| eRF1 (ETF1) | Eukaryotic release factor recognizing all three stop codons | Central to termination; implicated in cancer |
| eRF3 (GSPT1) | GTPase that stimulates eRF1 | Regulates termination; target in cancer |
| mtRF1 | Mitochondrial release factor with specific codon recognition | Mitochondrial disease relevance |
| MTRF1L | Mitochondrial release factor-like protein | Substrate specificity studies |
| Hsp104 | Protein-remodeling factor affecting [PSI+] prion propagation | Model for termination readthrough |
| eIF3 | Initiation factor that facilitates eRF1 loading | Links initiation and termination |
| PABPC1 | Poly(A)-binding protein, interacts with eRF3 | Modulates termination |
| UPF1 | Nonsense-mediated decay factor | Couples termination to mRNA quality control |
| UPF2 | NMD factor | Interacts with release factors |
| UPF3 | NMD factor | Regulates termination-associated decay |
| DCP1 | Decapping enzyme, involved in NMD | Downstream of termination |
| XRN1 | Exonuclease, degrades mRNA after NMD | Termination-coupled decay |
| GCN1 | Ribosome-associated factor, regulates translation | Stress response |
| RPS3 | Ribosomal protein, part of decoding center | Affects termination fidelity |
How Is translation release factor activity, codon specific Regulated?
Codon-specific release factor activity is regulated at multiple levels. In eukaryotes, the interaction between eRF1 and eRF3 is modulated by GTP binding and hydrolysis, and by factors such as eIF3 and PABPC1. The abundance of release factors relative to suppressor tRNAs influences readthrough efficiency. Ribosomal dynamics, including translocation accuracy, can affect termination. Additionally, stress conditions can alter translation termination through the integrated stress response, though direct evidence for GO:0016149 regulation via mTOR is not provided in the cited literature. Post-translational modifications of release factors may also play a role, but specific details are beyond the scope of the verified citations.
translation release factor activity, codon specific and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| eRF1 (ETF1) | Cancer, nonsense mutation diseases | CRISPR knockout in cancer cell lines |
| eRF3 (GSPT1) | Cancer, translation termination defects | Point mutation knock-in to disrupt GTPase activity |
| mtRF1 | Mitochondrial disorders | Knockout in mitochondrial disease models |
| MTRF1L | Mitochondrial translation defects | Overexpression in patient-derived fibroblasts |
| UPF1 | Nonsense-mediated decay, cancer | Knockout to study termination-coupled decay |
Nonsense Mutation Diseases
Premature stop codons caused by nonsense mutations lead to truncated proteins and disease. Codon-specific release factors recognize these premature stops, and modulating their activity or promoting readthrough is a therapeutic strategy. Diseases such as cystic fibrosis, Duchenne muscular dystrophy, and beta-thalassemia are linked to nonsense mutations. Understanding release factor specificity is crucial for designing drugs that selectively suppress premature termination without affecting normal stops.
Cancer
Dysregulation of translation termination can contribute to cancer. Mutations in eRF1 or eRF3, or alterations in their expression, have been observed in various cancers. For example, eRF3 (GSPT1) is a target for anticancer drugs that induce its degradation, leading to termination defects and apoptosis in cancer cells. The interplay between termination and nonsense-mediated decay also affects tumor suppressor gene expression.
Mitochondrial Disorders
Mitochondrial release factors are essential for mitochondrial protein synthesis. Mutations in mtRF1 or MTRF1L can impair mitochondrial translation, leading to mitochondrial diseases such as Leigh syndrome or cardiomyopathy. The substrate specificity of mitochondrial release factors differs from cytosolic ones, and some organisms lack response to UGA. Studying these factors helps understand mitochondrial disease mechanisms.
From translation release factor activity, codon specific-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of eRF1 affect termination efficiency? | CRISPR knockout in HEK293T cells |
| Can a point mutation in eRF3 alter GTP hydrolysis? | CRISPR point mutation knock-in |
| What is the effect of mtRF1 overexpression on mitochondrial translation? | CRISPR overexpression in HeLa cells |
| How does a tagged release factor localize in cells? | Tagged knock-in with fluorescent protein |
| Does suppression of a release factor promote readthrough? | CRISPR knockout in reporter cell lines |
| Can CRISPR library screening identify modifiers of termination? | Genome-wide CRISPR screen |
How to Study the translation release factor activity, codon specific Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribosome profiling | Ribosome occupancy at stop codons | Global termination efficiency |
| In vitro translation | Peptide release activity | Codon specificity of release factors |
| CRISPR knockout | Loss-of-function effects | Essentiality of release factor genes |
| CRISPR point mutation | Effect of specific amino acid changes | Mechanistic studies of catalytic residues |
| CRISPR knock-in | Tagged protein localization and interactions | Live-cell imaging |
| Overexpression | Gain-of-function phenotypes | Dominant effects of release factors |
| CRISPR library screening | Identification of modifiers | Genome-wide analysis of termination |
| Proteomics | Protein interactions and abundance | Complex composition |
Ribosome Profiling
Ribosome profiling (Ribo-seq) provides a snapshot of ribosome positions on mRNAs, allowing researchers to assess termination efficiency and stop codon readthrough. It can detect changes in release factor activity by measuring ribosome occupancy at stop codons. This method is powerful for studying codon-specific effects and has been used to investigate translation dynamics.
In Vitro Translation Assays
In vitro translation systems using purified components can directly measure release factor activity. These assays often use reporter mRNAs with specific stop codons and detect released polypeptides. They are used to study codon specificity and the effects of mutations in release factors. Such assays have been instrumental in defining the substrate specificity of mitochondrial release factors.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and point mutation models enable functional dissection of release factor genes in cells. Knockout of eRF1 or eRF3 can reveal their essential roles in viability and termination. Point mutations can mimic disease-associated variants or disrupt catalytic activity. Overexpression models can test gain-of-function effects. These approaches are complemented by CRISPR library screening to identify modifiers of termination.
Proteomics and Mass Spectrometry
Mass spectrometry-based proteomics can identify proteins associated with release factors and quantify changes in protein expression upon perturbation. For example, immunoprecipitation of eRF1 followed by mass spectrometry can reveal interacting partners. This method helps elucidate the termination complex and its regulation.
How CRISPR Can Be Used to Study GO:0016149 translation release factor activity, codon specific
Knockout
CRISPR knockout of release factor genes such as eRF1 or eRF3 can be used to study their essentiality and effects on translation termination. For example, knockout of eRF1 in cell lines leads to increased readthrough and cell death, highlighting its critical role. Knockout models are valuable for dissecting codon-specific functions and identifying compensatory mechanisms.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific amino acid substitutions in release factor genes to study their catalytic activity or interactions. For instance, mutating the GGQ motif in eRF1 abolishes peptide release. Such models are crucial for understanding the molecular basis of codon specificity and for modeling disease-associated mutations.
Knock-in
CRISPR knock-in can be used to tag release factors with fluorescent proteins or epitope tags for localization and interaction studies. Tagged eRF1 or eRF3 can be imaged in live cells to track their recruitment to ribosomes. Knock-in of reporter genes with specific stop codons can also be used to measure readthrough efficiency.
Overexpression
CRISPR-mediated overexpression of release factors can be achieved by inserting a strong promoter or multiple gene copies. Overexpression of eRF1 or eRF3 may enhance termination efficiency or cause dominant-negative effects. This approach is useful for studying gain-of-function phenotypes and for producing large amounts of release factors for biochemical assays.
How EDITGENE Supports translation release factor activity, codon specific Research
Researchers studying translation release factor activity, codon specific-related genes often need to determine whether a candidate gene is causally involved in termination, how mutations affect codon specificity, and what downstream pathways are perturbed. EDITGENE provides a comprehensive suite of CRISPR services to address these questions, from generating knockout cell lines to performing genome-wide screens.
Contact EDITGENE today to design your custom CRISPR model for translation release factor activity, codon specific research.
Frequently Asked Questions About translation release factor activity, codon specific
What is GO:0016149?
GO:0016149 is a Gene Ontology molecular function term for translation release factor activity that is specific for one or more termination codons, acting at the ribosomal A-site with polypeptidyl-tRNA at the P-site.
What genes are involved in translation release factor activity, codon specific?
Key genes include RF1, RF2, eRF1 (ETF1), eRF3 (GSPT1), mtRF1, and MTRF1L, among others.
How does codon-specific release factor work?
It recognizes a stop codon in the ribosomal A-site and catalyzes hydrolysis of the peptidyl-tRNA bond, releasing the polypeptide.
What diseases are associated with defects in translation termination?
Nonsense mutation diseases, cancer, and mitochondrial disorders are linked to defects in release factor activity.
What methods are used to study translation release factor activity?
Ribosome profiling, in vitro translation assays, CRISPR knockout/knock-in, and proteomics are commonly used.
Can CRISPR be used to model codon-specific release factor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional studies of release factor genes.
What is the role of eRF1 in translation termination?
eRF1 recognizes all three stop codons and catalyzes peptide release in eukaryotes.
How do suppressor tRNAs affect termination?
Suppressor tRNAs compete with release factors for stop codon recognition, leading to readthrough.
What is the difference between bacterial and eukaryotic release factors?
Bacteria have codon-specific RF1 and RF2, while eukaryotes have a single eRF1 that recognizes all stop codons.
Why is mitochondrial release factor specificity important?
Mitochondrial release factors have distinct codon specificity, and their dysfunction causes mitochondrial diseases.
Conclusion
GO:0016149, translation release factor activity, codon specific, is a fundamental molecular function that ensures accurate termination of protein synthesis. Its dysregulation is implicated in a range of human diseases, from nonsense mutation disorders to cancer and mitochondrial diseases. Advances in CRISPR technology and ribosome profiling have greatly enhanced our ability to study this process. EDITGENE provides comprehensive CRISPR services to model release factor activity, enabling researchers to dissect mechanisms and develop therapeutic strategies.
References
- 1. Rodnina MV et al.. 2017. Ribosome dynamics during decoding.. Philos Trans R Soc Lond B Biol Sci 372(1716) PMID: 28138068
- 2. Bhat SY et al.. 2025. Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases.. Nucleic Acids Res 53(6) PMID: 40156864
- 3. Takahashi A et al.. 2007. A systematic evaluation of the function of the protein-remodeling factor Hsp104 in [PSI+] prion propagation in S. cerevisiae by comprehensive chromosomal mutations.. Prion 1(1):69-77 PMID: 19164920
- 4. Nadler F et al.. 2023. Translation termination in human mitochondria - substrate specificity of mitochondrial release factors.. Biol Chem 404(8-9):769-779 PMID: 37377370
- 5. Djumagulov M et al.. 2021. Accuracy mechanism of eukaryotic ribosome translocation.. Nature 600(7889):543-546 PMID: 34853469
- 6. Inagaki Y et al.. 1993. Lack of peptide-release activity responding to codon UGA in Mycoplasma capricolum.. Nucleic Acids Res 21(6):1335-8 PMID: 8464722
- 7. Shuvalova E et al.. 2026. Eukaryotic initiation factor eIF3 facilitates loading of eukaryotic release factor eRF1 or suppressor tRNA to the ribosome.. Nucleic Acids Res 54(1) PMID: 41521665
- 8. Doronina VA et al.. 2008. Site-specific release of nascent chains from ribosomes at a sense codon.. Mol Cell Biol 28(13):4227-39 PMID: 18458056
